Preview Mode Links will not work in preview mode

Feb 22, 2021

Featuring an interview with Dr Kathleen Moore on the following topics:

  • Recent data with PARP inhibitors and immune checkpoint inhibitors for advanced ovarian cancer (0:00)
  • Efficacy of lenvatinib alone and in combination with pembrolizumab in patients with previously treated ovarian cancer (34:23)
  • Activity of mirvetuximab soravtansine alone and with bevacizumab in patients with ovarian cancer (36:23)
  • Incidence of acute myeloid leukemia and myelodysplastic syndromes in the Phase III SOLO-2 trial assessing maintenance olaparib for patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (39:30)
  • Case: A woman in her early 40s with metastatic ovarian cancer and a BRCA1 mutation receives olaparib as maintenance therapy (44:25)
  • Case: A woman in her late 40s develops anemia after receiving maintenance olaparib for advanced ovarian cancer with a BRCA mutation (54:24)
  • Counseling patients with ovarian cancer about the side effects associated with PARP inhibitors (1:01:57)
  • Integration of PARP inhibitors into the therapeutic algorithm for ovarian cancer (1:09:23)

CME information and select publications